News Details

BeiGene to Present at the 38th Annual J.P. Morgan Healthcare Conference

BeiGene to Present at the 38th Annual J.P. Morgan Healthcare Conference

Jan 08, 2020 7:30 AM

CAMBRIDGE, Mass. and BEIJING, China, Jan. 08, 2020 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer, today announced that the company will present at the 38th Annual J.P. Morgan Healthcare Conference in San Francisco. The presentation is scheduled for 10:00 a.m. PT on Wednesday, January 15, 2020.

A live webcast can be accessed from the investors section of BeiGene’s website at An archived replay will be available for 90 days following the event.

About BeiGene

BeiGene is a global, commercial-stage, research-based biotechnology company focused on molecularly-targeted and immuno-oncology cancer therapeutics. With a team of over 3,300 employees in China, the United States, Australia and Europe, BeiGene is advancing a pipeline consisting of novel oral small molecules and monoclonal antibodies for cancer. BeiGene is also working to create combination solutions aimed to have both a meaningful and lasting impact on cancer patients. In the United States, BeiGene markets BRUKINSA™ (zanubrutinib) and in China, the Company has received approval to market its anti-PD-1 antibody tislelizumab and markets ABRAXANE® (paclitaxel for injection [albumin bound]), REVLIMID® (lenalidomide), and VIDAZA® (azacitidine) under a license from Celgene Logistics Sarl, a Bristol-Myers Squibb company, and plans to market XGEVA® (denosumab) under a license from Amgen.1,[2]

Investor Contact
Craig West
+1 857-302-5189

Media Contact
Liza Heapes or Vivian Ni
+1 857-302-5663 or +1 857-302-7596

ABRAXANE® is registered trademark of Abraxis Bioscience LLC, a Bristol-Myers Squibb company; REVLIMID® and VIDAZA® are registered trademarks of Celgene Corporation, a Bristol-Myers Squibb company. 

2 XGEVA® is a registered trademark of Amgen.


Source: BeiGene, LTD.